These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7660147)

  • 1. Defibrotide reduces monocyte PAI-2 and procoagulant activity.
    Abbate R; Gori AM; Martini F; Attanasio M; Comeglio P; Giusti B; Zarone N; Francalanci I; Prisco D; Gensini GF
    Semin Thromb Hemost; 1995; 21(2):245-50. PubMed ID: 7660147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells.
    Falanga A; Vignoli A; Marchetti M; Barbui T
    Leukemia; 2003 Aug; 17(8):1636-42. PubMed ID: 12886253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
    Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
    Echart CL; Graziadio B; Somaini S; Ferro LI; Richardson PG; Fareed J; Iacobelli M
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel insight into the mechanism of the antithrombotic action of defibrotide.
    Tettamanti R; Bianchi G; Vitte PA; Kato G; Porta R; Thiemermann C; Pescador R; Mantovani M
    Life Sci; 1992; 51(19):1545-55. PubMed ID: 1331634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro inhibition by defibrotide of monocyte superoxide anion generation: a possible mechanism for the antithrombotic effect of a polydeoxyribonucleotide-derived drug.
    Cirillo F; Margaglione M; Vecchione G; Ames PR; Coppola A; Grandone E; Cerbone AM; Marelli C; Di Minno G
    Haemostasis; 1991; 21(2):98-105. PubMed ID: 1660014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.
    Violi F; Ferro D; Saliola M; Quintarelli C; Basili S; Balsano F
    Eur J Clin Pharmacol; 1992; 42(4):379-83. PubMed ID: 1516602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defibrotide inhibits platelet activation by cathepsin G released from stimulated polymorphonuclear leukocytes.
    Evangelista V; Piccardoni P; de Gaetano G; Cerletti C
    Thromb Haemost; 1992 Jun; 67(6):660-4. PubMed ID: 1509406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrated view of the activities of defibrotide.
    Pescador R; Porta R; Ferro L
    Semin Thromb Hemost; 1996; 22 Suppl 1():71-5. PubMed ID: 8807733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of venous endothelial activity and transcellular calcium transport by defibrotide: the adenosine hypothesis.
    Pasini FL; Frigerio C; Capecchi PL; Ceccatelli L; Messa GL; Franchi M; Di Perri T
    Semin Thromb Hemost; 1996; 22 Suppl 1():15-20. PubMed ID: 8807723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of defibrotide against myocardial ischemia and decline of beta-adrenoceptor function in the rabbit.
    Berti F; Rossoni G; Niada R; Omini C; Pretolani M; Mandelli C
    Haemostasis; 1986; 16 Suppl 1():13-7. PubMed ID: 3011616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficient fibrinolytic response in patients with Raynaud's phenomenon and its correction with defibrotide.
    Cimminiello C; Milani M; Pietra A; Rossi F; Aloisio M; Nazzari M; Bonfardeci G
    Semin Thromb Hemost; 1991; 17 Suppl 1():106-11. PubMed ID: 2068563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man.
    Coccheri S; Biagi G; Legnani C; Bianchini B; Grauso F
    Eur J Clin Pharmacol; 1988; 35(2):151-6. PubMed ID: 3191933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defibrotide in vitro inhibits neutrophil activation by a Ca++-involving mechanism.
    Di Perri T; Laghi Pasini F; Capecchi PL; Ceccatelli L; Pasqui AL; Orrico A
    Int J Tissue React; 1987; 9(5):399-406. PubMed ID: 3667109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness of defibrotide in vaso-occlusive disorders and its mode of actions.
    Ulutin ON
    Semin Thromb Hemost; 1988; 14 Suppl():58-63. PubMed ID: 2848323
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.
    Ulutin ON; Cizmeci G; Balkuv-Ulutin S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):177-80. PubMed ID: 2459016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.
    Echart CL; Somaini S; Distaso M; Palumbo A; Richardson PG; Fareed J; Iacobelli M
    Clin Appl Thromb Hemost; 2012; 18(1):79-86. PubMed ID: 21733935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of defibrotide on platelet function.
    Ulutin ON; Balkuv-Ulutin S; Bezer-Göker B; Cizmeci G; Ferhanoğlu B; Ozsoy Y; Uğur MS; Ulutin T; Yaman A; Yardimci T
    Semin Thromb Hemost; 1996; 22 Suppl 1():21-4. PubMed ID: 8807724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology and clinical pharmacology of defibrotide: a new profibrinolytic, antithrombotic and anti-platelet substance.
    Ulutin ON; Balkuv-Ulutin S; Ugur MS; Ulutin T; Ozsoy Y; Cizmeci G
    Adv Exp Med Biol; 1990; 281():429-38. PubMed ID: 2102624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defibrotide as a possible anti-ischemic drug.
    Coccheri S; Nazzari M
    Semin Thromb Hemost; 1996; 22 Suppl 1():9-14. PubMed ID: 8807722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.